Skip to content

Clinical Study to Evaluate Effectiveness of Digital Refraction

A Prospective Clinical Study to Evaluate the Effectiveness of Digital Refraction

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03502863
Enrollment
102
Registered
2018-04-19
Start date
2018-04-19
Completion date
2018-07-06
Last updated
2018-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Astigmatism, Myopia

Brief summary

Prospective, comparative, randomized, non-masked clinical study to compare the a digital refraction with LogMAR VA testing utilizing trial lenses, to standard manual refraction using a Phoropter, and LogMAR VA testing, in accuracy of visual acuity measurement.

Detailed description

A digital refraction tool is a device meant to measure visual acuity and to subjectively measure refractive value for a patient's eye for the conditions of myopia and astigmatism. It is intended for adults aged 22 to 55 years that have no prior correction with up to 3.00 diopters (D) of myopia and up to 2.00 D of astigmatism, or those with prior correction up to 10.00 D of myopia and require an over-refraction of no more than 2.75 D. LogMAR (ETDRS) chart to measure visual acuity. The manual manifest refraction is performed by an eyecare specialist using a phoropter. The LogMAR Visual Acuity chart is used to measure visual acuity. The manual refraction will be used in this study for obtaining the refractive error of each eye.

Interventions

DEVICEDigital refraction

A web-based application for obtaining the refractive error and visual acuity of each eye, using a computer and a smart phone.

OTHERManual Refraction

Manual refraction and ETDRS chart

Sponsors

Visibly
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
22 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

1. Subject must be between 22 and 55 years of age at the time of consent. 2. Subject must have a refractive error 1. With no greater than -3.00 D myopia and -2.00 D astigmatism in either eye. 2. With prior correction of no greater than -10.00 D myopia and requiring over-refraction of no more than 2.75 D in either eye. 5\. Subjects with Best Corrected Visual Acuity (BCVA) of 20/32 or better.

Exclusion criteria

1. Subjects with diabetes mellitus. 2. Subjects using ophthalmic or systemic corticosteroids. 3. Subjects with autoimmune conditions. 4. Subjects with active corneal or conjunctival infection. 5. Subjects with active corneal, conjunctival, or intraocular inflammation (ie, uveitis). 6. Subjects with diabetic retinopathy. 7. Subjects with glaucoma or ocular hypertension. 8. Subjects with macular degeneration. 9. Subjects with previous ocular surgery. 10. Subjects on antihyperglycemic agents; corticosteroids; hydroxychloroquine (Plaquenil) and chloroquine (Aralen); tamoxifen (Nolvadex). 11. Pregnancy 12. Subjects who, in the judgment of the Investigator, may be inappropriate for the intended study procedures.

Design outcomes

Primary

MeasureTime frameDescription
A digital refraction will be compared to standard manual refraction methods (using a phoropter) to the correlation of the two methods.After the Day 1 VisitsThe difference between testing methods (Manual Refraction with a phoropter versus a digital refraction test) will be analyzed by mean, standard deviation, and 95% confidence interval overall and by the levels of refractive correction (sphere, cylinder, MRSE) and for visual acuity using LogMAR format.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026